Skip to content

Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0

Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02509377
Acronym
MOMSto40BMI
Enrollment
1
Registered
2015-07-28
Start date
2015-07-31
Completion date
2017-05-31
Last updated
2018-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelomeningocele, Pregnancy

Keywords

Fetal Surgery, Open Fetal Surgery, Elevated BMI, Body Mass Index, Spina Bifida

Brief summary

Inclusion and exclusion criteria for fetal repair of MMC was established by the Management of Myelomeningocele Study (MOMS Trial) and these criteria are the standard of care throughout the United States. These criteria state exclusion for hypertension and diabetes which are known co-morbidities for obesity. Investigators plan to expand one exclusion criteria for open fetal repair surgery. Currently, an exclusion factor is a maternal BMI of 35.0 and greater.Investigators will maintain all other inclusion and exclusion criteria (including excluding for hypertension and diabetes) with the exception of expanding the BMI to include mothers with a BMI of 35.0 to 40.0. Co-morbidities of the research group will be compared to the comorbidities of the mothers published in the MOMS trial.

Detailed description

The MOMS trial proved prenatal repair of myelomeningocele was an advantage over postnatal repair for the fetus/neonate/child and is the standard of care for maternal/fetal dyads who meet the inclusion exclusion criteria. Investigators plan to maintain all inclusion exclusion criteria for open fetal repair surgery of myelomeningocele with one exception, the expansion of the maternal BMI to 40.0. This population of mothers with a BMI of 35.0 to 40.0 have not been studied. The morbidities of these mothers will be compared to morbidities of mothers with a BMI less than or equal to 34.9 currently in the scientific literature.

Interventions

Open Fetal Repair of Myelomeningocele when mothers BMI is elevated

Sponsors

St. Louis University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Maternal BMI 35.0 to 40.0 * No maternal documented co-morbidities * Fetal MMC begins between thoracic 1 and sacral 1, on the spinal column. * Evidence of fetal hindbrain herniation (hindbrain is being pulled down the spinal column). * A gestational age is between 19 weeks 0 days and 26 weeks with evidence of placental membrane fusion. * Documented normal fetal karyotype.

Exclusion criteria

* History of maternal alloimmunization problem * Kell sensitization * Risk of preterm birth * History of spontaneous preterm birth * Cervix \<20mm in length * Presence of cerclage * Placental problem * History of placental abruption * Placental Previa * Body-mass index of 40.1 or more * Maternal contraindication to surgery * Insulin-dependent pregestational diabetes * Hypertension or preeclampsia * HIV, hepatitis-B, or hepatitis-C positive * Other medical condition of risk to mother * Uterine problem * Previous hysterotomy in the active uterine segment * Severe fibroids * Uterine malformation (bicornuate, arcuate, unicornuate, didelphys) * No support person for periprocedural period * Inadequate support at home for pregnancy * Inadequate understanding of risks and benefits of fetal surgery * Inability to comply with medical restrictions, follow up after fetal surgery * Multiple gestation pregnancy (twins, triplets, etc.) * A fetal anomaly unrelated to myelomeningocele (heart defect, lung lesions) * Severe fetal kyphosis \>30 degrees (curvature of the back)

Design outcomes

Primary

MeasureTime frameDescription
Co-morbidities in mothers having fetal MMC repairup to 40 weeksMeasure the co-morbidity of mothers with a BMI of 35.0 to 40.0. Compare to published data in the MOMS trial.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026